The notable raises from March 2026

Several biotech companies closed significant rounds this month, spanning everything from novel cancer immunotherapy platforms to computational tools for lab automation. What stands out is the diversity of approaches attracting capital — and the recurring theme of data and technology sitting at the center of each one.

Crossbow Therapeutics — $77M, Series B

Crossbow pulled in the largest disclosed round of the month with a $77 million Series B. The company is developing next-generation T-cell engagers for oncology — a class of therapeutics that has shown real promise in hematologic cancers and is now being pushed into solid tumors. The raise will fund clinical development and manufacturing scale-up for their lead programs. T-cell engagers have been a hot space since the success of earlier bispecific antibody platforms, and Crossbow's approach appears to have caught the attention of investors looking for differentiated programs in immuno-oncology.

Congruence Therapeutics — $40M, Series B

Congruence closed a $40 million Series B to continue advancing its protein degradation pipeline. The company recently announced the first patient dosed in a Phase 1 trial, which likely gave investors the confidence to double down. Protein degradation — particularly through targeted degraders and molecular glues — has been gaining momentum as a therapeutic modality, and Congruence is positioning itself as a computationally driven player in that space. This round signals that investors are moving beyond platform-only bets and rewarding companies that can show clinical-stage progress.

AutoScience — $14M

AutoScience raised $14 million to scale its AI-powered platform for automating laboratory research workflows. This is an interesting one because AutoScience sits at the intersection of lab operations and artificial intelligence — a combination that is increasingly relevant as biotech labs look for ways to do more with less. Their platform is designed to reduce the manual overhead of routine experiments, freeing up scientists to focus on higher-value work. For labs that are already investing in digital infrastructure, companies like AutoScience represent the next logical step.

Antiverse — $9.3M, Series A

Cardiff-based Antiverse secured a $9.3 million Series A for its AI-based antibody discovery platform. The company uses deep learning to design novel antibodies, which positions it in the growing field of computationally designed biologics. What makes Antiverse noteworthy is its geographic footprint — the raise is another data point showing that biotech innovation and investment are spreading beyond the traditional Boston-San Francisco corridor. European biotechs with strong AI capabilities are increasingly competitive in attracting global venture capital.

VALANX Biotech — 3M Euro

VALANX Biotech raised 3 million euros to advance its antibody-drug conjugate program targeting breast cancer. ADCs have been one of the most active therapeutic areas in oncology over the past few years, with several major approvals validating the class. VALANX is early-stage, but the continued investor appetite for ADC programs — even at the seed and pre-clinical level — suggests that the market believes there is still meaningful room for innovation in this space.

Turquoise Health — $40M, Series C

While not a traditional biotech play, Turquoise Health's $40 million Series C is worth noting because it addresses a pain point that touches the entire healthcare ecosystem: pricing transparency. The company builds infrastructure for healthcare cost data, and its raise reflects the broader trend of investors backing companies that improve the operational and financial plumbing of life sciences and healthcare delivery.

What the March 2026 numbers tell us

Three patterns stand out when you look at this month's raises together.

Oncology remains the dominant category

Cancer therapeutics — T-cell engagers, ADCs, protein degradation — continue to attract the largest checks. This is not surprising given the clinical validation that these modalities have received in recent years, but it does underscore that investors still see significant unmet need and commercial opportunity in oncology. For biotech startups thinking about their fundraising positioning, being in or adjacent to oncology continues to be an advantage.

AI is no longer a differentiator — it is table stakes

Three of the six companies that raised in March have AI or computational biology at the core of their platform. Antiverse uses machine learning for antibody design. AutoScience applies AI to lab workflow automation. Congruence leverages computational approaches for target identification. The signal is clear: investors expect biotech companies to have a data and technology strategy. A wet-lab-only approach without computational augmentation is increasingly hard to fund at scale.

Data infrastructure is becoming a funding prerequisite

This is the less obvious but arguably most important trend. The companies raising the largest rounds are the ones with clean data systems underpinning their operations. They can demonstrate reproducible results, structured datasets, and audit-ready documentation — all of which are table stakes for due diligence in 2026. Investors are explicitly asking about data infrastructure during fundraising conversations, and the companies that cannot answer those questions convincingly are losing out to the ones that can.

What this means for early-stage biotech teams

If your startup is planning to raise in the next six to twelve months, the March 2026 funding landscape offers a few practical takeaways.

Invest in your data stack before you pitch. Investors are looking at how you manage experimental data, not just what results you have generated. A modern LIMS, a structured ELN, and a centralized inventory system signal operational maturity — and that signal matters more than ever. Tools like Genemod are built specifically for this purpose, giving biotech teams the data backbone that investors want to see.

Tell a clear clinical or translational story. The companies that raised the most this month had concrete milestones — a first patient dosed, a platform with validated outputs, a program entering clinical development. Investors are rewarding progress over promise. Your pitch needs to show a clear path from where you are today to the next value-creating milestone.

Build reproducibility into your workflows. When a prospective investor asks to see your raw data from a key experiment, how long does it take you to produce it? If the answer is more than a few minutes — because the data is spread across spreadsheets, local hard drives, and instrument computers — that is a red flag. The labs that run on centralized platforms can pull up any experiment, any sample record, and any protocol version on demand. That kind of operational confidence makes a real impression in a diligence process.

Looking ahead

March 2026 confirms what many in the industry have been feeling: biotech funding is healthy, but it is becoming more selective. Capital is flowing toward companies with strong science, clinical-stage progress, and robust operational infrastructure. The bar for what it takes to raise a competitive round continues to rise — and the teams that invest in their data systems, documentation practices, and lab technology today are the ones that will be best positioned to clear that bar tomorrow.

If you are building a biotech startup and want to make sure your lab infrastructure is investor-ready, Genemod provides the LIMS, ELN, and inventory management that growing teams need — all in one platform, built for the way modern labs actually work.